Analysis of the risk reduction of prophylactic partial mastectomy in @entity35 with XXXX -induced @entity0 .

@entity35 @entity106 @entity5 @entity0
The effectiveness of prophylactic mastectomy in preventing @entity0 was studied in female albino @entity35 . Group A served as untreated controls. Groups B, C, and D underwent 50%, 75%, and total mastectomies 2 weeks after the administration of @entity106 ( @entity106 ). Group E was initially subjected to total mastectomy. Two weeks after surgery, group E received 5 mg of @entity106 intravenously. Group F underwent sham procedures. All animals were sacrificed at age 8 months. The mean number of @entity5 per animal developing in groups A through E was 5.00, 5.17, 4.67, 5.46, and 5.20, respectively. There was 0.21 @entity5 per animal in group F. The mean time to @entity5 development in groups A through E was 11.33, 10.05, 9.88, 19.25, and 19.38 weeks, respectively. All results were subjected to an analysis of variance. There was no statistically significant difference in the number of @entity106 -induced @entity5 in groups A through E. Groups D and E had a significant prolonged time to @entity5 development. The overall risk of the development of @entity0 was not significantly reduced by prophylactic mastectomy. Residual breast tissue after prophylactic mastectomy is at increased risk for the development of @entity0 . The risk of developing @entity0 in this model is not reduced in proportion to the amount of breast tissue removed. (This study suggests that subcutaneous mastectomy in high-risk individuals may not have appropriate prophylaxis against the development of carcinoma of the breast.)
